Tianjin TEDA Biomedical Engineering Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Tianjin TEDA Biomedical Engineering.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Chemicals earnings growth	46.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) 26% Share Price Plunge Could Signal Some Risk

May 07

Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?

Sep 12

Investors Give Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shares A 28% Hiding

Apr 17

Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?

Apr 07

Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?

Nov 01

Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of Debt

Apr 21

Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?

Oct 26

Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?

Apr 06

Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?

Dec 22

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tianjin TEDA Biomedical Engineering has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:8189 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	398	-15	-16	-13	N/A
9/30/2023	450	-24	N/A	N/A	N/A
6/30/2023	430	-26	4	11	N/A
3/31/2023	447	-28	N/A	N/A	N/A
12/31/2022	404	-25	-22	-13	N/A
9/30/2022	424	-66	N/A	N/A	N/A
6/30/2022	440	-56	-76	-46	N/A
3/31/2022	441	-48	N/A	N/A	N/A
12/31/2021	476	-42	-34	-7	N/A
9/30/2021	475	-30	N/A	N/A	N/A
6/30/2021	446	-42	57	64	N/A
3/31/2021	425	-43	N/A	N/A	N/A
12/31/2020	369	-48	30	36	N/A
9/30/2020	326	-86	N/A	N/A	N/A
6/30/2020	323	-83	10	11	N/A
3/31/2020	314	-87	N/A	N/A	N/A
12/31/2019	359	-85	-5	-4	N/A
9/30/2019	367	-133	N/A	N/A	N/A
6/30/2019	376	-176	-20	-15	N/A
3/31/2019	382	-174	N/A	N/A	N/A
12/31/2018	352	-178	-32	-23	N/A
9/30/2018	396	-60	N/A	N/A	N/A
6/30/2018	395	-16	13	28	N/A
3/31/2018	391	-18	N/A	N/A	N/A
12/31/2017	376	-14	4	17	N/A
9/30/2017	336	-19	N/A	N/A	N/A
6/30/2017	337	-9	N/A	9	N/A
3/31/2017	368	1	N/A	N/A	N/A
12/31/2016	389	6	N/A	-7	N/A
9/30/2016	382	17	N/A	N/A	N/A
6/30/2016	470	27	N/A	-31	N/A
3/31/2016	481	24	N/A	N/A	N/A
12/31/2015	502	27	N/A	-32	N/A
9/30/2015	467	29	N/A	N/A	N/A
6/30/2015	435	20	N/A	-16	N/A
3/31/2015	442	22	N/A	N/A	N/A
12/31/2014	470	21	N/A	19	N/A
9/30/2014	543	20	N/A	N/A	N/A
6/30/2014	541	19	N/A	-11	N/A
3/31/2014	548	15	N/A	N/A	N/A
12/31/2013	583	21	N/A	-11	N/A
9/30/2013	659	33	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 8189's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if 8189's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 8189's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8189's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 8189's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8189's Return on Equity is forecast to be high in 3 years time

Tianjin TEDA Biomedical Engineering Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Tianjin Teda Biomedical Engineering Company Limited Appoints Mr. Tu Xiangzhen as the Independent Non-Executive Director

Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) 26% Share Price Plunge Could Signal Some Risk

Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.015 loss in FY 2022)

Tianjin TEDA Biomedical Engineering Company Limited Announces Resignation of Mr. Li Xudong as Independent Non-Executive Director and Chairman of the Audit Committee

Tianjin TEDA Biomedical Engineering Company Limited Announces Chief Executive Officer Changes

Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2023 Final Results on Mar 28, 2024

Third quarter 2023 earnings released: CN¥0.003 loss per share (vs CN¥0.004 loss in 3Q 2022)

Tianjin TEDA Biomedical Engineering Company Limited to Report Q3, 2023 Results on Nov 09, 2023

Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?

Second quarter 2023 earnings released: CN¥0.003 loss per share (vs CN¥0.004 loss in 2Q 2022)

Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2023 Results on Aug 10, 2023

Investors Give Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shares A 28% Hiding

Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?

Full year 2022 earnings released: CN¥0.015 loss per share (vs CN¥0.022 loss in FY 2021)

Less than half of directors are independent

Tianjin TEDA Biomedical Engineering Company Limited Announces Mr. Hao Zhihui Will Retire as an Executive Director

Third quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥0.001 profit in 3Q 2021)

Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?

Tianjin TEDA Biomedical Engineering Company Limited to Report Nine Months, 2022 Results on Nov 10, 2022

Tianjin Teda Biomedical Engineering Company Limited Announces Executive Changes

Second quarter 2022 earnings released

Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2022 Results on Aug 09, 2022

Tianjin TEDA Biomedical Engineering Company Limited (SEHK:8189) entered into the Equity Transfer Agreement to acquire Shanghai Weidi Network Technology Company from three shareholders for CNY12.8 million.

First quarter 2022 earnings released: CN¥0.003 loss per share (vs CN¥0 in 1Q 2021)

Less than half of directors are independent

Tianjin TEDA Biomedical Engineering Company Limited to Report Q1, 2022 Results on May 10, 2022

Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of Debt

Full year 2021 earnings released

Tianjin TEDA Biomedical Engineering Company Limited Approves Appointment of Mr. Zhao Zhiyou as the Independent Supervisor

Third quarter 2021 earnings released: EPS CN¥0.001 (vs CN¥0.006 loss in 3Q 2020)

Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?

Second quarter 2021 earnings released

Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥0.025 loss per share (vs CN¥0.045 loss in FY 2019)

Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?

Tianjin TEDA Biomedical Engineering Company Limited to Report Q3, 2020 Results on Nov 10, 2020

First half earnings released

Earnings released

Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2020 Results on Aug 10, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies